Эндометриоз: поиск фарматерапевтического компромисса

Н. Ф. Захаренко, Н. В. Косей, Л. М. Коломиец
In: Reproductive Endocrinology · 2012 · vol. 0(4) , pp. 52–57 · doi:10.18370/2309-4117.2012.4.52-57 · W1494904098
article OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-05 ⓘ

Endometriosis is a common gynecological pathology affecting 5-10% of reproductive-aged women and up to 30% of infertile women, impacting active populations regardless of ethnicity or social status.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-27 · read from full text ⓘ

This review article examines the clinical significance of endometriosis, noting its high prevalence among women of reproductive age and its status as a leading gynecological pathology alongside pelvic inflammatory disease and uterine fibroids. The authors highlight that the condition disproportionately affects active segments of the female population regardless of ethnic or social background, contributing to significant morbidity including infertility. The text references multiple international guidelines and studies comparing various pharmacological treatments, such as dienogest and GnRH analogs, for managing symptoms and improving outcomes after surgery. This paper is centrally about endometriosis — specifically discussing its epidemiology, impact on fertility, and the search for optimal pharmaceutical therapeutic compromises.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Уже много лет эндометриоз, без преувеличения, представляет собой предмет пристального внимания клиницистов. Это обусловлено тем, что данное заболевание входит в тройку лидеров патологий женской половой системы, уступая лишь воспалительным заболеваниям придатков и миоме матки. По оценкам различных авторов, частота эндометриоза у женщин репродуктивного возраста составляет от 5 до 10% и достигает 15-30% среди пациенток с первичным или вторичным бесплодием [1, 2]. Усугубляет положение тот факт, что эндометриоз не имеет «популяционной тропности» и поражает наиболее активную часть женской популяции, т.е. встречается преимущественно у женщин репродуктивного возраста вне зависимости от этнической и социальной принадлежности.
Full text 3,561 characters · extracted from oa-doi-fallback · click to expand
Эндометриоз: поиск фарматерапевтического компромисса DOI: https://doi.org/10.18370/2309-4117.2012.4.52-57Abstract Уже много лет эндометриоз, без преувеличения, представляет собой предмет пристального внимания клиницистов. Это обусловлено тем, что данное заболевание входит в тройку лидеров патологий женской половой системы, уступая лишь воспалительным заболеваниям придатков и миоме матки. По оценкам различных авторов, частота эндометриоза у женщин репродуктивного возраста составляет от 5 до 10% и достигает 15-30% среди пациенток с первичным или вторичным бесплодием [1, 2]. Усугубляет положение тот факт, что эндометриоз не имеет «популяционной тропности» и поражает наиболее активную часть женской популяции, т.е. встречается преимущественно у женщин репродуктивного возраста вне зависимости от этнической и социальной принадлежности.References - ESHRE guideline for the diagnosis and treatment of endometriosis. June 2007. - RCOG Standart: Investigation аnd Management оf Endometriosis. October 2006. - SOGC Clinical Practice Guideline: Endometriosis: Diagnosis and Management. July 2010. - Joseph C. Gambone et al. Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process. Chronic Pelvic Pain/Endometriosis Working Group, UCLA Medical School, Los Angeles, California Fertility аnd Sterility. 2002. Vol. 78, Nо. 5. - Cosson M., Querleu D., Donnez J., Madelenat P., Koninckx P., Audebert A., Manhes H. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertility and Sterility. April 2002, Vol. 77, No. 4. - Filicori M., Flamigni C., Cognigni G., Dellai P. Rossella arnone, angela falbo, and maurizio capelli. Comparison of the Suppressive Capacity of Different Depot Gonadotropin-Releasing Hormone Analogs in Women. Journal of Clinicei Endocrinology and Metabolism. 1993. Vol. 17, No. 1. - Strowitzki1 T., Marr J., Gerlinger C., Faustmann T., Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction, 2010. Vol. 00, No. 0, 1-9 pp. - Tasuku Harada, Mikio Momoeda, Yuji Taketani, Takeshi Aso, Masao Fukunaga, Hiroshi Hagino, Naoki Terakawa. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis – a randomized, double-blind, multicenter, controlled trial. Fertility and Sterility. 2008. - Леваков С.А., Хамошина М.Б. Эндометриоз: мировой прорыв в медикаментозном лечении. – М.: Редакция журнала Status Praesens, 2012. – 16 с. Downloads Published How to Cite Issue Section License Copyright (c) 2014 Н. Ф. Захаренко, Н. В. Косей, Л. М. Коломиец This work is licensed under a Creative Commons Attribution 4.0 International License. Authors who publish with this journal agree to the following terms: - Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (7)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK